GT Biopharma is trading at $5.14, up 6.16% in pre-market, with biotech-sector strength a possible explanation.
- The price compares with the November 4 close of $4.84; no fresh company-specific announcement explaining the move surfaced in the search.
- The previously announced SITC oral presentation is scheduled for November 6. Its October 26 announcement does not establish a cause for the rise.